Could a higher dose of an old asthma drug help kids breathe easier in an emergency?
NCT ID NCT05819541
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study tests whether a high dose of montelukast (Singulair), given by mouth, can help children aged 4 to 12 who are in the hospital with a moderate or severe asthma attack. The goal is to find the best dose for a future larger study. Children receive either the high-dose montelukast plus standard care (albuterol and steroids) or standard care alone. Researchers measure drug levels in the blood and track how quickly symptoms improve.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Montelukast (Singulair)
- What this could lead to
- If successful, this could lead to a new treatment option for children having severe asthma attacks, potentially reducing hospital stays and improving breathing faster.
- What could go wrong
- This is an early-phase dose-finding study, not a proof of effectiveness. The drug may not improve outcomes, and high doses could cause side effects like headache or stomach upset.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ASTHMA EXACERBATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Monroe Carell Jr. Children's Hospital at Vanderbilt
Nashville, Tennessee, 37232-9001, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.